Goldberg novel is finalist in Jewish Book award

Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake

Prediction market exchanges have allowed the public to bet on the ousting of Nicolás Maduro, the outcome of the Spain v. Argentina World Cup final, and whether Trump will use the word “hippopotamus” in the month of July.

July 31, 2026

Vol.52 No.30

By Sara Willa Ernst

White House

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

In his latest set of sweeping tariffs on the pharmaceutical industry, President Donald Trump has announced a 200% levy on imported generic drugs by the year 2029.

July 31, 2026

Vol.52 No.30

By Jacquelyn Cobb

Clinical Trials & Tribulations

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

The recent retraction of the LungTIME-C01 randomized trial evaluating chrono-modulated immunotherapy in non-small cell lung cancer has ignited a vigorous debate regarding the promise of cancer chronotherapy.

July 31, 2026

Vol.52 No.30

By Zachary S. Buchwald and Michael C. Lowe

Cancer History Project

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

If a Mount Rushmore of Epidemiology were to exist, Joseph F. Fraumeni Jr. would be etched into the face of the mountain, former NCI Director Ned Sharpless once told Stephen J. Chanock.

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

FDA’s Oncology Center of Excellence has published three final guidance documents intended to broaden eligibility criteria for participation in clinical trials of oncology drugs.

HHS releases government-wide policy to prohibit gain-of-function research

The Trump Administration has released a new United States Government Policy for Stopping High-Risk Life Sciences Research, a framework that prohibits federally supported dangerous gain-of-function research while establishing stronger oversight for life sciences research that could pose significant risks to public health, biosecurity, or national security.

July 31, 2026

Vol.52 No.30

By Claire Marie Porter

Goldberg novel is finalist in Jewish Book award

YOU MAY BE INTERESTED IN

Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

HHS releases government-wide policy to prohibit gain-of-function research

Renew today!

Subscriber content

Never miss an issue!

Login

Goldberg novel is finalist in Jewish Book award

YOU MAY BE INTERESTED IN

Prediction markets now allow betting on clinical trial results, FDA decisionsIt’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”Chanock and Brawley reflect on their illustrious mentor

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

HHS releases government-wide policy to prohibit gain-of-function research

Never miss an issue!

Login

Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor